Close
  Indian J Med Microbiol
 

Figure 3: reSURFACE-1 trial PASI response at week 12 for tildrakizumab 200 mg, 100 mg, and placebo

Figure 3: reSURFACE-1 trial PASI response at week 12 for tildrakizumab 200 mg, 100 mg, and placebo